Stock 4553 TOWA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Towa Pharmaceutical Co., Ltd. Share Price

Equities

4553

JP3623150004

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 11:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
2,773 JPY -0.11% Intraday chart for Towa Pharmaceutical Co., Ltd. +0.84% +17.90%
25/03 Towa Pharmaceutical Completes Payment for Director Stock Compensation MT
07/03 VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI

Financials

Sales 2024 * 230B 1.45B 121B Sales 2025 * 246B 1.55B 129B Capitalization 136B 862M 71.86B
Net income 2024 * 12.72B 80.27M 6.69B Net income 2025 * 11.66B 73.6M 6.14B EV / Sales 2024 * 1.3 x
Net Debt 2024 * 163B 1.03B 85.57B Net Debt 2025 * 162B 1.02B 85.13B EV / Sales 2025 * 1.21 x
P/E ratio 2024 *
10.7 x
P/E ratio 2025 *
11.7 x
Employees 4,298
Yield 2024 *
2.16%
Yield 2025 *
2.18%
Free-Float 47.46%
More Fundamentals * Assessed data

Chart Towa Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Completes Payment for Director Stock Compensation MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG). CI
Towa Pharmaceutical Co., Ltd. agreed to acquire Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG) for ¥47.7 billion. CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd. CI
Luye Pharma : Strikes Licensing Deal with Japan's Towa Pharma for Alzheimer's Disease Drug MT
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. CI
Innophys Co., Ltd. announced that it has received ¥3.53 billion in funding from a group of investors CI
Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. CI
Innophys Co., Ltd. announced that it expects to receive funding from Hi-Lex Corporation CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2016; Provides Earnings Guidance for the Full Year Ending March 2016; Revises Capital Expenditure Guidance for the Year Endings March 2017 and 2018 CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016 CI
Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016. CI
More news

Analyst Recommendations on Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Completes Payment for Director Stock Compensation MT
More recommendations

Press releases Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical : FY2023(1st quarter) Summary of Consolidated Financial Results for the Three Months Ended June 30, 2023(Based on Japanese GAAP) (375K/7P) PU
Towa Pharmaceutical : FY2023(1st quarter) Supplementary Material of Financial Results (1.03M/28P) PU
Towa Pharmaceutical : Notice of the 67th Ordinary General Meeting of Shareholders （176KB／10P） PU
Towa Pharmaceutical : FY2022 Supplementary Material of Financial Results (1.2M/42P) PU
Towa Pharmaceutical : FY2022(4th quarter) Summary of Consolidated Financial Results for the Year Ended March 31, 2023(Based on Japanese GAAP) (616K/10P) PU
More press releases

Quotes and Performance

1 day-0.11%
1 week+0.84%
Current month-4.51%
1 month-6.44%
3 months+11.28%
6 months+2.63%
Current year+17.90%
More quotes

Highs and lows

1 week
2 730.00
Extreme 2730
2 825.00
1 month
2 712.00
Extreme 2712
2 973.00
Current year
2 326.00
Extreme 2326
3 240.00
1 year
1 703.00
Extreme 1703
3 240.00
3 years
1 703.00
Extreme 1703
3 560.00
5 years
1 703.00
Extreme 1703
3 560.00
10 years
1 193.33
Extreme 1193.3333
3 560.00
More quotes

Managers and Directors - Towa Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Itsuro Yoshida PSD
 President 73 01/79/01
Kenichi Inoue ADM
 Chief Administrative Officer - -
Norikazu Inoue BRD
 Director/Board Member - -
Members of the board TitleAgeSince
Itsuro Yoshida PSD
 President 73 01/79/01
Sadayuki Morino PRN
 Corporate Officer/Principal 70 01/81/01
Norikazu Eiki BRD
 Director/Board Member 76 01/15/01
More insiders

ETFs positioned on Towa Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
0.17% 15 M€ +7.34%
NOMURA NEXT FUNDS JPX-NIKKEI INDEX 400 ETF - JPY ETF Nomura NEXT FUNDS JPX-Nikkei Index 400 ETF - JPY
0.01% 10,207 M€ +14.32%
More ETFs positioned on Towa Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
26/24/26 2,773 -0.11% 94,800
25/24/25 2,776 -1.03% 80,900
24/24/24 2,805 +0.36% 93,000
23/24/23 2,795 +0.11% 37,700
22/24/22 2,792 +1.53% 65,800

Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST

More quotes

Company Profile

Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Sector
Pharmaceuticals
Calendar
14/05/2024 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Towa Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2,773 JPY
Average target price
3,690 JPY
Spread / Average Target
+33.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TOWA PHARMACEUTICAL CO., LTD. Stock Towa Pharmaceutical Co., Ltd.
+17.90% 867M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4553 Stock